Transferrin-guided intelligent nanovesicles augment the targetability and potency of clinical PLK1 inhibitor to acute myeloid leukemia

Acute myeloid leukemia (AML) remains a most lethal hematological malignancy, partly because of its slow development of targeted therapies compared with other cancers. PLK1 inhibitor, volasertib (Vol), is among the few molecular targeted drugs granted breakthrough therapy status for AML; however, its...

Descripción completa

Detalles Bibliográficos
Autores principales: Xia, Yifeng, An, Jingnan, Li, Jiaying, Gu, Wenxing, Zhang, Yifan, Zhao, Songsong, Zhao, Cenzhu, Xu, Yang, Li, Bin, Zhong, Zhiyuan, Meng, Fenghua
Formato: Online Artículo Texto
Lenguaje:English
Publicado: KeAi Publishing 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494038/
https://www.ncbi.nlm.nih.gov/pubmed/36185744
http://dx.doi.org/10.1016/j.bioactmat.2022.08.032

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9494038/
https://www.ncbi.nlm.nih.gov/pubmed/36185744
http://dx.doi.org/10.1016/j.bioactmat.2022.08.032

Ejemplares similares